Polysaccharide Enzymatic Hydrolysate Suppresses the Growth of Human Colon Cancer Cells Via Inducing Apoptosis
Overview
General Surgery
Authors
Affiliations
is a popular traditional Chinese medicine used in China to improve health. Previous researches have revealed that the polysaccharide from could exert diversity activities, including immunomodulation, antioxidant, and antitumor effects. However, the effect of enzymatically hydrolyzed polysaccharide (EGLP) in colorectal cancer (CRC) progression remains unknown. The present research aimed to investigate the antitumor mechanism of EGLP in human colon cancer cells. For this purpose, the cytotoxic effects of EGLP were measured by the (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) method. The apoptosis was evoked upon EGLP treatment, which was assayed using flow cytometry. The results indicated that EGLP may induce apoptosis in human colon cancer cell (HCT-116) cells via the upregulation of BCL-2 associated X protein (Bax), phospho-extracellular regulated protein kinases (P-ERK), and cleaved caspase-3 expression and downregulation of B-cell lymphoma-2 (Bcl-2), phospho-serine/threonine kinase 1 (p-Akt1), and cyclo-oxygen-ase (COX-2) expression. The obtained findings indicated EGLP as a new therapeutic agent in fighting CRC.
Guo K, Wang Z, Su X Chin J Integr Med. 2024; .
PMID: 39331211 DOI: 10.1007/s11655-024-4115-8.
Shi M Reprod Sci. 2024; 31(7):1881-1894.
PMID: 38448739 PMC: 11217070. DOI: 10.1007/s43032-024-01500-3.
Mousavi S, Hashemi S, Gholami A, Omidifar N, Chiang W, Neralla V Sci Rep. 2023; 13(1):17326.
PMID: 37833299 PMC: 10576041. DOI: 10.1038/s41598-023-44135-1.
A review of anti-tumour effects of Ganoderma lucidum in gastrointestinal cancer.
Ye T, Ge Y, Jiang X, Song H, Peng C, Liu B Chin Med. 2023; 18(1):107.
PMID: 37641070 PMC: 10463474. DOI: 10.1186/s13020-023-00811-y.
Research Progress on the Anticancer Activities and Mechanisms of Polysaccharides From .
Wang M, Yu F Front Pharmacol. 2022; 13:891171.
PMID: 35865946 PMC: 9294232. DOI: 10.3389/fphar.2022.891171.